Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma

BACKGROUND: Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of response. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Serratì, Simona, Di Fonte, Roberta, Porcelli, Letizia, De Summa, Simona, De Risi, Ivana, Fucci, Livia, Ruggieri, Eustachio, Marvulli, Tommaso Maria, Strippoli, Sabino, Fasano, Rossella, Rafaschieri, Tania, Guida, Gabriella, Guida, Michele, Azzariti, Amalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538246/
https://www.ncbi.nlm.nih.gov/pubmed/37759291
http://dx.doi.org/10.1186/s13046-023-02808-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538246/
https://www.ncbi.nlm.nih.gov/pubmed/37759291
http://dx.doi.org/10.1186/s13046-023-02808-9

Ejemplares similares